I think you’re making reference to Kite Pharma who was acquired by Gilead Sciences in 2017 for $11,9B and Juno Therapeutics acquired by Celgene in 2018 for $9B. But these are CAR-Ts liquid tumours only single target, prior to FDA approval & prior to revenues.
With the MOA demonstrated by Dr Bosch (ASCO early June BNOS & this week in Cambridge UK), how much is the value for NWBO?